Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Bullboard Posts
Comment by BigShoes13on Jan 27, 2014 4:35pm
96 Views
Post# 22139570

RE:RE:Explain this private placement.

RE:RE:Explain this private placement.Abirdseyeview,

Let's assume you are right that the PP is being filled in the US. It has been discussed here and said many times that it is being filled in the US but nobody has given any proof and I think nobody really knows.

Anyway, lets just assume it is. 

So what? This doesn't answer why it went ahead. To get exposure in the US?  HUH!!!

If we have the goods then we do not need to do a PP to get exposure. If we have management that does a huge PP for one-third of the company just to get US exposure then we are really in trouble.

The only reason a PP should be done is if the company needs working capital. That is what Neil has said is the reason.  If the company needs working capital then to me it shows that the $9.5 million from Wanbang is not coming any time soon. Also that there will not be much coming from Obagi... at least not soon.

Anyway, we have all been waiting for two NR's. One came today and our share price is down. I think that says a lot. A long time until the $2.00, or $5.00 as is often predicted here.
Bullboard Posts